XNCR  valuation analysis

Name: Xencor, Inc
Description: Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Feb 24, 2021
Market cap: $2.50B (985th)
Sales(TTM): $122.69M (1380th)
Earnings(TTM): -$69.33M (1151st)

FFER: 1.37 (why)
Actual price: $43.17
FFEThis is Xencor, Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $30.34
Quantile: XNCR is expensive given its fundamentals.
Prices as of EOD 2021-04-14
Price & Estimates
Sales & Earnings history (TTM)
  • Xencor, Inc's earnings decreased from $26.88M to -$69.33M in the last year.
  • Xencor, Inc's operating income decreased from $13.82M to -$76.80M in the last year.
Earnings / MarketCap
Xencor, Inc
"Biotechnology" industry
Sales / MarketCap
Xencor, Inc
"Biotechnology" industry
Book / MarketCap
Xencor, Inc
"Biotechnology" industry
Equity / Assets
Xencor, Inc
"Biotechnology" industry